Drugs / si-544
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06191042 | Jan 2024 → Jun 2025 | psoriasis, psoriatic arthritis | selectION Therapeutics GmbH | Completed | No outcome recorded |
| Phase 1 | NCT05383378 | Aug 2022 → Nov 2023 | atopic eczema | selectION Therapeutics GmbH | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | si-544 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05383378 ↗ |
| Route | Subcutaneous | “Subcutaneous injection in the abdomen” NCT05383378 ↗ |